What were the key drivers of Bristol-Myers Squibb's sales performance in Q3 2005?

Sales performance in Q3 2005 was driven by strong growth in key products such as PLAVIX*, ABILIFY*, REYATAZ, and ERBITUX*. This growth helped offset declines in older products like PRAVACHOL and TAXOL*, which faced increased competition and generic entry. Overall net sales remained flat year-over-year.

How did the sale of the Consumer Medicines business impact the company's financial results?

The sale of the U.S. and Canadian Consumer Medicines business in Q3 2005 generated a significant pre-tax gain of $569 million ($370 million net of tax). This gain contributed substantially to the reported increase in net earnings for both the third quarter and the first nine months of 2005.

What is the company's outlook regarding its product portfolio and future growth?

The company is strategically shifting its portfolio towards disease areas with high unmet needs and focusing on specialists and high-value physicians. While facing continued exclusivity losses for some products, the company anticipates growth from its in-line products, recent launches like ABILIFY* and REYATAZ, and potential new products such as ORENCIA*. However, the company also noted that changes in product mix will likely impact gross margins due to the higher margins of products facing exclusivity loss.

Are there any significant legal or regulatory issues that investors should be aware of?

Yes, Bristol-Myers Squibb is involved in several significant pending lawsuits, claims, proceedings, and investigations, including patent litigation concerning PLAVIX*. The company acknowledges that the aggregate impact of these legal matters, beyond current reserves, is reasonably likely to be material to its results of operations, cash flows, financial condition, and liquidity over the next few years.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q3 FY2005

Summary

Bristol-Myers Squibb Company (BMY) reported its financial results for the third quarter and the first nine months of 2005. For the third quarter, net sales remained flat year-over-year at $4.8 billion, with stable U.S. sales offset by a slight decline in international sales, impacted by foreign exchange. The company saw notable growth in key products like PLAVIX*, ABILIFY*, REYATAZ, and ERBITUX*. However, sales of PRAVACHOL and TAXOL* continued to decline due to increased competition and generic entry. Net earnings from continuing operations showed a significant increase of 28% for the quarter and 11% for the nine months, driven in part by a large gain from the sale of the Consumer Medicines business in Q3 2005. The company also reported an increase in R&D spending, reflecting ongoing investment in late-stage compounds. Despite an increase in the effective tax rate for the quarter, overall profitability improved, supported by strong product performance and cost management initiatives. The company continues to navigate significant legal proceedings, with potential material impacts on future operations.

Key Highlights

1Net sales for the third quarter of 2005 remained constant at $4.77 billion compared to the prior year's quarter, with stable U.S. sales and a slight decrease in international sales.
2Earnings from continuing operations for Q3 2005 increased by 28% to $964 million, and for the first nine months increased by 11% to $2.50 billion.
3Key product sales showed strong growth for PLAVIX* (up 9% in Q3), ABILIFY* (up 58% in Q3), REYATAZ (up 66% in Q3), and ERBITUX* (up 27% in Q3).
4Sales of PRAVACHOL and TAXOL* continued to decline, with PRAVACHOL sales down 12% in Q3 due to generic competition and increased market competition.
5The company recorded a significant pre-tax gain of $569 million ($370 million net of tax) from the sale of its U.S. and Canadian Consumer Medicines business in the third quarter.
6Research and development expenses increased by 9% to $669 million in Q3 2005, reflecting continued investment in late-stage compounds.
7The company's effective income tax rate increased to 31.2% for Q3 2005 from 20.9% in Q3 2004, primarily due to a higher concentration of earnings in the U.S. and lower foreign tax credits.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q3 Ended Sep 30, 2005

Summary

Key Highlights

Frequently Asked Questions